Felipe Samaniego

Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas

Qing Deng, Guangchun Han, Nahum Puebla‐Osorio et al. · Nature Medicine · 2020 · 561 citations · Full text

Lymphoid Neoplasia, Radiation Oncology, Cell Therapy +10

High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine

Jorge Romaguera, Luis Fayad, Maria Alma Rodriguez et al. · Journal of Clinical Oncology · 2005 · 557 citations · Full text

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

Jason R. Westin, Fuliang Chu, Min Zhang et al. · The Lancet Oncology · 2013 · 528 citations · Full text

Lymphoid Neoplasia, Medicine, Immunology +10

Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

André Goy, Anas Younes, Peter McLaughlin et al. · Journal of Clinical Oncology · 2004 · 526 citations · Full text

HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region

Hsiao C. Chang, Felipe Samaniego, Bala C. Nair et al. · AIDS · 1997 · 435 citations